MAL-PDT for difficult to treat nonmelanoma skin cancer

Dermatologic Therapy

Volumn 24, Issue 1, 2011, Pages 82-93

  Stebbins, William G ^a   Hanke, C William ^a  

^a Center of Indiana   (United States)

Author keywords

aminolevulinic acid; methyl aminolevulinic acid; nonmelanoma skin cancer; photodynamic therapy; review

Indexed keywords

AMINOLEVULINIC ACID; METHYL AMINOLEVULINIC ACD; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79551533404     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01381.x     Document Type: Article

References (45)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol 2006: 146: 283-287.
2. Miller DL, Weinstock MA,. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994: 30: 774-778.
3. Green A,. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol 1992: 1: 47-51.
4. Glass AG, Hoover RN,. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989: 262: 2097-2100.
5. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007: 56: 125-143.
6. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008: 18: 547-553.
7. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003: 149: 1242-1249.
8. Morton C, Horn M, Lehman J, Tack B, Bedane C, Tijoe M,. A 24-month update of a placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in patients with Bowen's disease. J Eur Acad Dermatol Venereol 2005: 19 (Suppl. 2): 237-238.
9. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000: 71: 724-729.
10. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008: 22: 1302-1311.
11. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for "difficult-to-treat" basal cell carcinoma. Br J Dermatol 2005: 152: 765-772.
12. Brancaleon L, Moseley H,. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002: 17: 173-186.
13. Szeimies RM,. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007: 25: 89-94.
14. Kennedy JC, Pottier RH, Pross DC,. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990: 6: 143-148.
15. Tierney E, Barker A, Ahdout J, Hanke CW, Moy RL, Kouba DJ,. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg 2009: 35: 725-746.
16. Martin A, Tope WD, Grevelink JM, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995: 287: 665-674.
17. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH,. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998: 134: 248-249.
18. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009: 48: 1236-1245.
19. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol 2007: 143: 1131-1136.
20. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE,. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001: 62: 140-145.
21. Angell-Petersen E, Sorensen R, Warloe T, et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006: 126: 265-271.
22. PhotoCure ASA,. Summary of product characteristics. Accessed January 4, 2011.
23. Soler AM, Warloe T, Berner A, Giercksky KE,. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001: 145: 467-471.
24. Szeimies RM, Morton CA, Sidoroff A, Braathen LR,. Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol 2005: 85: 483-490.
25. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy versus cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001: 144: 832-840.
26. Cox NH,. Body site distribution of Bowen's disease. Br J Dermatol 1994: 130: 714-716.
27. Kao GF,. Carcinoma arising in Bowen's disease. Arch Dermatol 1986: 122: 1124-1126.
28. Stables GI, Stringer MR, Robinson DJ, Ash DV,. Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997: 136: 957-960.
29. Morton CA, Whitehurst C, Moore JV, MacKie RM,. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000: 143: 767-772.
30. Britton JE, Goulden V, Stables G, Stringer M, Sheehan-Dare R,. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. Br J Dermatol 2005: 153: 780-784.
31. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994: 130: 743-751.
32. Fijan S, Honigsmann H, Ortel B,. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995: 133: 282-288.
33. Avram DK, Goldman MP,. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004: 3: S36-S39.
34. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006: 142: 729-735.
35. Calzavara-Pinton PG,. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995: 29: 53-57.
36. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P,. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998: 134: 821-826.
37. Fritsch C, Goerz G, Ruzicka T,. Photodynamic therapy in dermatology. Arch Dermatol 1998: 134: 207-214.
38. Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate- based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008: 159: 137-144.
39. Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008: 18: 539-546.
40. Caekelbergh K, Nikkels AF, Leroy B, Verhaeghe E, Lamotte M, Vincent R,. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol 2009: 8: 992-996.
41. Kaae J, Philipsen PA, Haedersdal M, Wulf HC,. Immediate whealing urticaria in red light exposed areas during photodynamic therapy. Acta Derm Venereol 2008: 88: 480-483.
42. Harries MJ, Street G, Gilmour E, Rhodes LE, Beck MH,. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photodermatol Photoimmunol Photomed 2007: 23: 35-36.
43. Choudhary S, Nouri K, Elsaie ML,. Photodynamic therapy in dermatology: a review. Lasers Med Sci 2009: 24: 971-980.
44. Rowe DE, Carroll RJ, Day CL Jr,. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989: 15: 315-328.
45. Downs AM, Bower CB, Oliver DA, Stone CA,. Methyl aminolaevulinate- photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation. Br J Dermatol 2009: 161: 189-190.